Elizabeth Smoot Malecha

Intercept Pharmaceuticals (United States) — United States

Medicine · Health Sciences

6h-index371citations44works17.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Liver Diseases and Immunity(36), Liver Disease Diagnosis and Treatment(21), Drug Transport and Resistance Mechanisms(19), Pediatric Hepatobiliary Diseases and Treatments(17), Gallbladder and Bile Duct Disorders(10)

Publications44 total

Correction to COBALT: A Confirmatory Trial of Obeticholic Acid in Primary Biliary Cholangitis With Placebo and External Controls
The American Journal of Gastroenterology·2024· 4 cited
COBALT: A Confirmatory Trial of Obeticholic Acid in Primary Biliary Cholangitis With Placebo and External Controls
The American Journal of Gastroenterology·2024· 47 citedOpen Access
Contents
JHEP Reports·2024Open Access
Contents
JHEP Reports·2023Open Access
Contents
JHEP Reports·2023Open Access
Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls
Gastroenterology·2022· 91 citedOpen Access
P09 Long-term obeticholic acid (OCA) for Primary Biliary Cholangitis (PBC) in a clinical trial improved event free survival (death, liver transplant and hepatic decompensation) compared to external controls from the GLOBAL PBC real-world database
Abstracts·2022· 1 cited
Long-term obeticholic acid (OCA) for primary biliary cholangitis (PBC) in a clinical trial improved event free survival (death, liver transplant and hepatic decompensation) compared to external controls from the GLOBAL PBC real-world database
Journal of Hepatology·2022
Contents
JHEP Reports·2022Open Access
Su1357: PATIENTS WITH PRIMARY BILIARY CHOLANGITIS TREATED WITH LONG-TERM OBETICHOLIC ACID IN A TRIAL-SETTING DEMONSTRATE BETTER EVENT-FREE SURVIVAL OUTCOMES THAN EXTERNAL CONTROLS FROM THE GLOBAL PBC AND UK-PBC STUDY GROUPS
Gastroenterology·2022· 1 cited
OC.04.7 LONG-TERM EFFICACY AND SAFETY OF OBETICHOLIC ACID IN PATIENTS WITH PBC FROM THE POISE TRIAL GROUPED BIOCHEMICALLY BY RISK OF DISEASE PROGRESSION
Digestive and Liver Disease·2021· 1 cited
Long-term efficacy and safety of obeticholic acid in patients with PBC from the POISE trial grouped biochemically by risk of disease progression
Digestive and Liver Disease·2021· 1 cited
Long-Term Efficacy and Safety of Obeticholic Acid in Patients With PBC From POISE Grouped by Risk of Disease Progression
Zeitschrift für Gastroenterologie·2021
P214 Predicted risk of end stage liver disease utilizing the UK-PBC risk score in PBC patients
2021Open Access
S0984 Long-Term Efficacy and Safety of Obeticholic Acid in Patients With Primary Biliary Cholangitis: A Demographic Subgroup Analysis of 5-Year Results From the POISE Trial
The American Journal of Gastroenterology·2020
Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis
JHEP Reports·2020· 16 citedOpen Access
T06.01.3 DURABLE RESPONSE IN THE MARKERS OF CHOLESTASIS THROUGH 5 YEARS OF OPEN-LABEL EXTENSION STUDY OF OBETICHOLIC ACID IN PRIMARY BILIARY CHOLANGITIS
Digestive and Liver Disease·2020
Durable response in the markers of cholestasis through 5 years of open-label extension study of obeticholic acid in primary biliary cholangitis
Zeitschrift für Gastroenterologie·2020· 2 cited
Durability of biochemical improvements through six years of open label treatment with obeticholic acid in patients with primary biliary cholangitis who did not achieve the poise criteria
Journal of Hepatology·2020Open Access
Predicted risk of end stage liver disease utilizing the UK-PBC risk score with continued standard of care and subsequent addition of obeticholic acid for 60 months in patients with primary biliary cholangitis
Journal of Hepatology·2020Open Access
page 1 of 3Next →

Frequent Co-authors

Leigh MacConell(31), Gideon M. Hirschfield(23), Michael Trauner(19), Christopher L. Bowlus(19), A. Sender Liberman(17), Richard Pencek(16), Albert Parés(16), Frederik Nevens(15), Pietro Andreoné(12), Annarosa Floreani(11), Marco Carbone(10), Marlyn J. Mayo(9), Bettina E. Hansen(9), Vı́ctor Vargas(8), Д. А. Шапиро(8), Douglas Thorburn(8), George Mells(8), Andreas E. Kremer(8), Mitchell L. Shiffman(7), Joost P.H. Drenth(7)